-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guided reading
The androgen and insulin-like growth factor-1 (IGF-1) regulatory axis is known to play critical roles in the progression of prostate cancer
The data and samples of this nested case-control study were derived from the large PCPT (SWOG-S9217) trial.
01The relationship between sex steroids and IGFs/IGFBPs and BMI
BMI was significantly associated with sex steroids and IGFs/IGFBPs
02Effect of sex steroids and IGFs/IGFPBs on obesity-related prostate cancer risk
Elevated BMI increased cancer risk in the high-risk group (OR=1.
Analysis conclusion
The present findings suggest that IGF-1 regulates axis-related serological markers, particularly IGFs and IGFBP2, that may influence obesity-related prostate cancer risk
.
More research is needed in the future to determine the role of these potential mediators, to understand the biological mechanisms associated with obesity and prostate cancer risk, and to help researchers and clinicians develop more effective prostate cancer prevention strategies and treatments
.
references:
Chau CH, Till C, Price DK, et al.
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial.
Endocr Relat Cancer.
2022 Jan 20;29(2):99-109 .
Editor: Wang Mumu
Reviewer: LR
Executive: Wang Mumu